Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.21 - $41.31
Previous CloseN/A
Volume154.73K
Average Volume (3M)526.25K
Market Cap
$653.13M
Enterprise ValueN/A
Total Cash (Recent Filing)$385.37M
Total Debt (Recent Filing)$16.04M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 11, 2025EPS Estimate
-1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding29,380,495
10 Day Avg. Volume596,965
30 Day Avg. Volume526,246
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.59
Price to Sales (P/S)0.00
P/FCF Ratio-4.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$46.00Price Target Upside110.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
AnaptysBio News
PremiumCompany Announcements
AnaptysBio Reports Positive Phase 2b Trial Results
PremiumCompany Announcements
AnaptysBio Reports Strong Q1 2025 Results and Progress
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Ph. II trial of rosnilimab in RA hit the primary endpoint and demonstrated benefit on key secondary endpoints.
Financial ProspectsANAB announced a $75M stock repurchase program, representing roughly 12% of the primary shares outstanding.
Strategic PartnershipsGSK reported Jemperli sales significantly above the consensus, which is positive for ANAB due to their financial collaboration.
Bears Say
Clinical Trial ChallengesANAB announced that the Ph. IIb trial of ANB032 did not meet the primary EASI-75 endpoint nor any secondary endpoints and will discontinue further development.
Competitive LandscapePeresolimab was discontinued in Phase 2b by Lilly due to results not aligning with those observed in Phase 2a, contrasting with ongoing trials for rosnilimab.
Financial PerformanceNet loss was $38M, compared to an estimated $22M.
Ownership Overview
43.85% Insiders
21.76% Mutual Funds
0.91% Other Institutional Investors
22.15% Public Companies and Individual Investors
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $653.13M.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Aug 11, 2025 which is in 68 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on May 05, 2025. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$1.253 by -$0.027.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.52.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 29,380,495 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.28 in its last earnings report, missing expectations of -$1.253. Following the earnings report the stock price went down -2.943%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
AnaptysBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.00 (110.43% Upside)
$46.00 (110.43% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.00%
12-Months-Change
Fundamentals
Return on Equity
-343.83%
Trailing 12-Months
Asset Growth
4.00%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company that specializes in the development of novel antibody therapies. Operating in the biopharmaceutical sector, AnaptysBio focuses primarily on the discovery and development of first-in-class immunology therapeutic antibodies aimed at treating inflammatory diseases. The company leverages its proprietary somatic hypermutation (SHM) antibody platform to generate high-affinity therapeutic antibodies against various biological targets.
ANAB Stock 12 Month Forecast
Average Price Target
$46.00
▲(110.43%Upside)